Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target, RBC Raises to $130 as 2026 Catalysts Come Into Focus
UBS reiterated a Buy rating on Boston Scientific, keeping its $140 price target and citing upside potential into 2026. RBC raised its target to $130, while Canaccord Genuity adjusted to $131. BSX shares opened near $92.93, down about 10% in a month, with a market cap around $138 billion. Analysts point to growth in cardiac devices but warn on valuation and policy risks.